Multiple Myeloma · line 3 · Idecabtagene vicleucel (ide-cel) BCMA CAR-T for triple-class-exposed R/R multiple myeloma — single infusion after Flu/Cy lymphodepletion (KarMMa)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-IDECEL-MM-3L |
| ID | IND-MM-RR-3L-IDECEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-ESMO-MM-2023 SRC-KARMMA-MUNSHI-2021 SRC-NCCN-MM-2025 |
Notes
STUB — requires two clinical co-lead signoffs before publication (CHARTER §6.1). KarMMa pivotal source available; NCCN-MM-2025 + ESMO-MM-2023 supplementary citations satisfy Q4 ≥2-source axis. Sibling to forthcoming IND-MM-RR-3L-CILTACEL (cilta-cel 3L); controversies block frames sequencing logic.
Used By
No reverse references found in the YAML corpus.